Corvus prices $69M follow-on

Cancer company Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) raised $69 million through the sale of 8.1 million shares at $8.50 in a follow-on underwritten by Credit Suisse, Jefferies, Guggenheim and Wed...